BioCryst stock surges post announcing Orladeyo revenue in FY21

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) posted its Orladeyo revenue for the full year 2021 on January 10, 2021. Thereafter, its stock started surging in the pre-market trading session. Moreover, it continued gaining in the trading session as well.

The BCRX stock was up by 16.61% and traded at $13.48 (gaining 1.92 points) at 10:21 a.m. ET. The market capitalization stood at $2.4 billion. The share volume traded was 2,496,080, which was closer to the average share volume of 2,943,093. Earlier, the BCRX stock lost a huge 17.8% in the previous week. The stock closed at $14.07 on January 3, 2022, and on Friday, it closed at $11.56 last week. However, due to today’s surge the stock has rebounded considerably.

Performance data for Orladeyo
  • ORLADEYO preliminary net revenue of $45.6 million for Q4 2021 and $122 million for FY 2021.
  • ORLADEYO net revenue expected to more than double in 2022 to no less than $250 million; Company expects ORLADEYO to become the market leader in HAE prophylaxis therapy with peak sales of $1 billion.
CEO’s Statement

“Following 12 months of a successful launch through a global pandemic, we have a clear picture of the continued commercial trajectory for ORLADEYO based on a very attractive product profile, leading to strong patient demand to switch from injectable therapies to our oral, once-daily medicine, with 70 percent patient retention through the first year. Building on our substantial 2021 patient base, we are confident that ORLADEYO will achieve no less than $250 million of net revenue in 2022 and that ORLADEYO will become the market leader as the most prescribed prophylactic therapy with peak sales of $1 billion.”

-said Jon Stonehouse, president and chief executive officer of BioCryst, in a press release.

It will be interesting to watch if the stock gains back the losses faced in the last week.

Related Posts